Compare DERM & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DERM | IMUX |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 155.8M |
| IPO Year | 2021 | 2013 |
| Metric | DERM | IMUX |
|---|---|---|
| Price | $6.19 | $7.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $13.75 | ★ $43.09 |
| AVG Volume (30 Days) | 175.0K | ★ 390.3K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.72 | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,858,000.00 | N/A |
| Revenue This Year | $31.55 | N/A |
| Revenue Next Year | $60.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.20 | N/A |
| 52 Week Low | $4.31 | $0.51 |
| 52 Week High | $9.56 | $17.43 |
| Indicator | DERM | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 23.86 |
| Support Level | $5.95 | $0.78 |
| Resistance Level | $6.59 | $15.82 |
| Average True Range (ATR) | 0.41 | 0.66 |
| MACD | -0.07 | -0.11 |
| Stochastic Oscillator | 9.18 | 2.51 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.